Cogstate Ltd
Company Profile
Business description
Cogstate Ltd is a cognitive science company. The principal activity of the group is the Creation, validation, and commercialisation of digital brain health assessments; and the Design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials, Healthcare, and Administration. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.
Contact
367 Collins Street
Level 32
MelbourneVIC3000
AUST: +61 396641300
Sector
Healthcare
Stock type
Defensive
Industry
Health Information Services
Fiscal Year End
30 June 2027
Employees
249
Stocks News & Analysis
stocks
Avoid these overvalued ASX shares
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
stocks
Lithium’s latest drop and what it means for ASX investors
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,995.70 | 5.50 | 0.06% |
| CAC 40 | 8,363.14 | 23.03 | 0.28% |
| DAX 40 | 25,011.35 | 164.66 | 0.66% |
| Dow JONES (US) | 52,224.64 | 385.38 | 0.74% |
| FTSE 100 | 10,585.91 | 61.15 | 0.58% |
| HKSE | 24,950.60 | 181.69 | -0.72% |
| NASDAQ | 25,837.21 | 329.13 | 1.29% |
| Nikkei 225 | 67,436.77 | 1,204.59 | 1.82% |
| NZX 50 Index | 13,691.46 | 35.43 | 0.26% |
| S&P 500 | 7,509.20 | 65.92 | 0.89% |
| S&P/ASX 200 | 8,811.20 | 4.70 | 0.05% |
| SSE Composite Index | 3,877.52 | 13.15 | 0.34% |